Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.9.3927

Serum Carcinoembryonic Antigen Levels before Initial Treatment are Associated with EGFR Mutations and EML4-ALK Fusion Gene in Lung Adenocarcinoma Patients  

Wang, Wen-Tao (Department of Thoracic Surgery, the Affiliated Tumor Hospital of Zhengzhou University)
Li, Yin (Department of Thoracic Surgery, the Affiliated Tumor Hospital of Zhengzhou University)
Ma, Jie (Department of Molecular Pathology, the Affiliated Tumor Hospital of Zhengzhou University)
Chen, Xiao-Bing (Department of Oncology, the Affiliated Tumor Hospital of Zhengzhou University)
Qin, Jian-Jun (Department of Thoracic Surgery, the Affiliated Tumor Hospital of Zhengzhou University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.9, 2014 , pp. 3927-3932 More about this Journal
Abstract
Background: Epidermal growth factor receptor (EGFR) mutations and echinoderm microtubule associated protein like 4-anaplastic lymphoma kinase (EML4-ALK) define specific molecular subsets of lung adenocarcinomas with distinct clinical features. Our purpose was to analyze clinical features and prognostic value of EGFR gene mutations and the EML4-ALK fusion gene in lung adenocarcinoma. Patients and Methods: EGFR gene mutations and the EML4-ALK fusion gene were detected in 92 lung adenocarcinoma patients in China. Tumor marker levels before first treatment were measured by electrochemiluminescence immunoassay. Results: EGFR mutations were found in 40.2% (37/92) of lung adenocarcinoma patients, being identified at high frequencies in never-smokers (48.3% vs. 26.5% in smokers; P=0.040) and in patients with abnormal serum carcinoembryonic antigen (CEA) levels before the initial treatment (58.3% vs. 28.6%, P=0.004). Multivariate analysis revealed that a higher serum CEA level before the initial treatment was independently associated with EGFR gene mutations (95%CI: 1.476~11.343, P=0.007). We also identified 8 patients who harbored the EML4-ALK fusion gene (8.7%, 8/92). In concordance with previous reports, younger age was a clinical feature for these (P=0.008). Seven of the positive cases were never smokers, and no coexistence with EGFR mutation was discovered. In addition, the frequency of the EML4-ALK fusion gene among patients with a serum CEA concentration below 5ng/ml seemed to be higher than patients with a concentration over 5ng/ml (P=0.021). No significant difference was observed for time to progression and overall survival between EML4-ALK-positive group and EML4-ALK-negative group or between patients with and without an EGFR mutation. Conclusions: The serum CEA level before the initial treatment may be helpful in screening population for EGFR mutations or EML4-ALK fusion gene presence in lung adenocarcinoma patients.
Keywords
Carcinoembryonic antigen; lung adenocarcinoma; EGFR mutations; EML4-ALK fusion gene;
Citations & Related Records
Times Cited By KSCI : 4  (Citation Analysis)
연도 인용수 순위
1 Shoji F, Yoshino I, Yano T, et al (2007). Serum carcinoembryonic antigen level is associated with epidermal growth factor receptor mutations in recurrent lung adenocarcinomas. Cancer, 110, 2793-8.   DOI   ScienceOn
2 Screaton RA, Penn LZ and Stanners CP (1997). Carcinoembryonic antigen, a human tumor marker, cooperates with Myc and Bcl-2 in cellular transformation. J Cell Biol, 137, 939-52.   DOI   ScienceOn
3 Shaw AT, Kim DW, Nakagawa K, et al (2013). Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med, 368, 2385-94.   DOI   ScienceOn
4 Shaw AT, Yeap BY, Mino-Kenudson M, et al (2009). Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol, 27, 4247-53.   DOI   ScienceOn
5 Soda M, Choi YL, Enomoto M, et al (2007). Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 448, 561-6.   DOI   ScienceOn
6 Usuda K, Sagawa M, Motono N, et al (2014). Relationships between EGFR mutation status of lung cancer and preoperative factors - are they predictive? Asian Pac J Cancer Prev, 15, 657-62.   과학기술학회마을   DOI   ScienceOn
7 Yatabe Y and Mitsudomi T (2007). Epidermal growth factor receptor mutations in lung cancers. Pathol Int, 57, 233-44.   DOI   ScienceOn
8 Zhang Y, Wang Q, Han ZG, et al (2013). Differences in epidermal growth factor receptor gene mutations and relationship with clinicopathological features in NSCLC between Uygur and Han ethnic groups. Asian Pac J Cancer Prev, 14, 2879-83.   과학기술학회마을   DOI   ScienceOn
9 Ordonez C, Screaton RA, Ilantzis C, et al (2000). Human carcinoembryonic antigen functions as a general inhibitor of anoikis. Cancer Res, 60, 3419-24.
10 Miyanaga A, Shimizu K, Noro R, et al (2013). Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation. BMC Cancer, 13, 262.   DOI   ScienceOn
11 Nagai Y, Miyazawa H, Huqun, et al (2005). Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res, 65, 7276-82.   DOI   ScienceOn
12 Okamoto T, Nakamura T, Ikeda J, et al (2005). Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer. Eur J Cancer, 41, 1286-90.   DOI   ScienceOn
13 Ravindranath N, Wion D, Brachet P, et al (2001). Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate. J Androl, 22, 432-43.
14 Ozgul MA, G KRL, Seyhan EC, et al (2013). The maximum standardized FDG uptake on PET-CT in patients with non-small cell lung cancer. Multidiscip Respir Med, 8, 69.   DOI   ScienceOn
15 Planchard D (2013). Identification of driver mutations in lung cancer: first step in personalized cancer. Target Oncol, 8, 3-14.   DOI   ScienceOn
16 Qin HF, Qu LL, Liu H, et al (2013). Serum CEA level change and its significance before and after gefitinib therapy on patients with advanced non-small cell lung cancer. Asian Pac J Cancer Prev, 14, 4205-8.   과학기술학회마을   DOI   ScienceOn
17 Scaltriti M and Baselga J (2006). The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res, 12, 5268-72.   DOI   ScienceOn
18 Herbst RS (2004). Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys, 59, 21-6.   DOI   ScienceOn
19 Dearden S, Stevens J, Wu YL, et al (2013). Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol, 24, 2371-6.   DOI   ScienceOn
20 Fukuoka M, Wu YL, Thongprasert S, et al (2011). Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol, 29, 2866-74.   DOI   ScienceOn
21 Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.   DOI
22 Gahr S, Stoehr R, Geissinger E, et al (2013). EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice. Br J Cancer, 109, 1821-8.   DOI   ScienceOn
23 Horinouchi H, Sekine I, Sumi M, et al (2012). Brain metastases after definitive concurrent chemoradiotherapy in patients with stage III lung adenocarcinoma: carcinoembryonic antigen as a potential predictive factor. Cancer Sci, 103, 756-9.   DOI   ScienceOn
24 Ishiguro F, Fukui T, Mori S, et al (2010). Serum carcinoembryonic antigen level as a surrogate marker for the evaluation of tumor response to chemotherapy in nonsmall cell lung cancer. Ann Thorac Cardiovasc Surg, 16, 242-7.
25 Maemondo M, Inoue A, Kobayashi K, et al (2010). Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med, 362, 2380-8.   DOI   ScienceOn
26 Blumenthal RD, Hansen HJ and Goldenberg DM (2005). Inhibition of adhesion, invasion, and metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5 (Carcinoembryonic Antigen). Cancer Res, 65, 8809-17.   DOI   ScienceOn
27 Aydiner A, Yildiz I and Seyidova A (2013). Clinical outcomes and prognostic factors associated with the response to erlotinib in non-small-cell lung cancer patients with unknown EGFR mutational status. Asian Pac J Cancer Prev, 14, 3255-61.   과학기술학회마을   DOI   ScienceOn
28 Benchimol S, Fuks A, Jothy S, et al (1989). Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell, 57, 327-34.   DOI   ScienceOn
29 Cook MB, Dawsey SM, Freedman ND, et al (2009). Sex disparities in cancer incidence by period and age. Cancer Epidemiol Biomarkers Prev, 18, 1174-82.   DOI   ScienceOn
30 Bergman B, Brezicka FT, Engstrom CP, et al (1993). Clinical usefulness of serum assays of neuron-specific enolase, carcinoembryonic antigen and CA-50 antigen in the diagnosis of lung cancer. Eur J Cancer, 29A, 198-202.
31 Wu YC, Chang IC, Wang CL, et al (2013). Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan. PLoS One, 8, e70839.   DOI
32 Li Y, Li Y, Yang T, et al (2013). Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer. PLoS One, 8, e52093.   DOI
33 Choi YL, Sun JM, Cho J, et al (2013). EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospital. PLoS One, 8, e56011.   DOI